A Houston vet has seen growth in business for her mobile vet company due to the pandemic. Now, she's planning major growth. Photo courtesy of Rollin' Vets

It's safe to say that the real winners of work-from-home trends that sparked due to the pandemic are our pets. Dogs and cats that were used to not seeing their owners for eight hours every work day now have 24-hour access to attention, treats, and ear scratches.

This increased attention pets are getting from their owners has also meant an increased awareness of pet health, says Katie Eick, founder of Houston-based Rollin' Vets, a startup that has mobilized veterinary services.

"People are home and observing their animals more. They're seeing and recognizing things they might not have if they were at work all day," Eick says.

Each of the four mobile units can do most everything a brick-and-mortar clinic can. Photo courtesy of Rollin' Vets

That's, of course, not the only way the pandemic has affected business for Eick. She founded her company in 2016 and was seeing steady growth as delivery and on-demand services like Uber, DoorDash, etc. increased in use and awareness.

"We were continuously growing slowly — then COVID hit. It really cemented that … all the convenience services are in the forefront of people's minds." Eick tells InnovationMap. "COVID made it clear that this was a necessary service."

Like a lot of businesses, vet clinics closed to the public and only accept drop-off patients. This new way of seeing pets coupled with the fact that most people are working remotely from home also played to the advantage Rollin' Vets — why drive your pet to drop off at a clinic when the vet can come to your driveway?

COVID-19 closures and social distancing practices also called for a rise in veterinary telemedicine — something that Eick says has been challenging for her to utilize both due to the board of medicine having strict regulations in place as well as the challenges trying to provide virtual animal care poses.

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

"Humans can get on and tell you their symptoms, where they hurt, and how they are feeling. Animals can't do that," Eick says.

Earlier in the pandemic, she did provide some telemedicine visits. The board, which bans telemedicine care for pets not previously seen by a vet or pets that haven't been seen in over a year, loosened the regulations to allow for virtual care of pets if the vet has ever seen the animal. This was helpful for providing refill medications, for instance.

Then, Eick had an appointment with a four-year-old French bulldog that changed her mindset on telemedicine. The dog had some stomach issues when his owner made an appointment with Eick. By the time she got to the dog, he had more or less seemed fine — he was eating again and didn't seem despondent in any way. But when Eick performed his exam, she found a mass.

"If I would have just looked at that dog over a video chat, he would have died," Eick says, adding that she got the dog right into surgery at a nearby facility.

In this case, telemedicine wouldn't have provided a solution for the animal, but Eick hasn't ruled virtual care out in general.

"I do think there's place for it, but we have to be really careful," she says.

At this point, Eick has more than proven her value proposition for her company. She has four mobile units with a team of four vets, six technicians, and four receptionists. As far as funding goes, she's pitched to the Houston Angel Network and is looking for angel investors. She's also planning on looking into crowdfunding as an option.

She's planning for growth — starting with Dallas and San Antonio — and sees the company adopting a franchise model that will eventually take Rollin' Vets out of state.

"We're aiming to be a nationwide brand," Eick says.

Rollin' Vets is planning to fundraise on NextSeed next month. Photo courtesy of Rollin' Vets

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Houston-based veterinary biotech startup modernizes cancer treatments for dogs

Paw-dern medicine

More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies recently accomplished a significant milestone. In October, CAVU's specialized immunotherapy was administered to its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals."

At CAVU, O'Connor dedicates her time to modernizing cancer care for dogs by developing an Autologous Prescription Product, otherwise known as adoptive T-cell therapy for dogs. The T-cell therapy is currently offered as a companion treatment to other canine cancer treatments, such as chemotherapy, radiation or surgery, O'Connor said.

Historically, cancer research for animals has lagged behind that of humans, and cancer diagnoses have come late due to the language barrier, O'Connor said. Of the dogs who enter remission, a majority of them relapse within 10 months to one year, she said.

"A majority [of dogs] are diagnosed at stage four, and you have to become very aggressive," O'Connor said. "For B-cell lymphoma, with the current treatments right now and the current standard of [therapies], less than 20 percent make it to two years post-diagnosis."

Launching CAVU
O'Connor first began studying T-cell therapy for humans with cancer during her post-doctoral fellowship at M.D. Anderson Cancer Center. Her fellowship also partnered with Texas A&M University's Small Animal Hospital to develop a clinical trial studying the effects of adoptive T-cell therapies on dogs with B-cell lymphoma.

T-cell therapy is a cellular-based treatment in which a type of white blood cells — or the cells that fight off tumors and infections — are harvested from blood samples drawn from patients. The cells are then injected back into the patient through an IV to fight the cancerous cells, O'Connor said.

Unexpectedly, O'Connor's 19-year-old dog, Bubbles, was diagnosed with transitional cell carcinoma in 2008 and later dying from it in December 2009. Five years later, O'Connor's sister's 6-year-old dog, Daisy, also died from transitional cell carcinoma. O'Connor said she remembers feeling helpless as she watched the dogs succumb to the disease.

"I was giving them drugs and protocols that were from 1980 … and I was really upset that there wasn't much more we could do for our dogs — especially because I treat my dogs like family," O'Connor said.

That was when O'Connor realized she wanted to help prevent other people from feeling the pain of losing their furry family members. While T-cell therapy is not a new method of treating cancer in humans, O'Connor focused on modifying the serum to create a treatment plan appropriate for dogs.

However, launching a company focusing specifically on treating cancer in animals was not without its challenges; O'Connor said she had to learn how to start a business, make industry connections, and adopt an entrepreneurial mindset.

To help with this, CAVU also connected with various entrepreneurial accelerators, such as Houston Technology Center and Station Houston, which are associations that help place young businesses in front of investors.

CAVU later became a member of the Houston Angel Network — a group of private investors of high net worth individuals that as a group invest in startups. By presenting her business to HAN and its investors, CAVU was able to gain financial backing.

CAVU also recently joined the Capital Factory in early 2018, an Austin-based accelerator program for entrepreneurs in Texas. O'Connor said the program has helped her meet investors, mentors and other startups.

"The way I overcame a lot of this [the early challenges] is by education, listening and trying to navigate and talk with as many of the right people as I could that had experience," she said.

The future of CAVU
Since CAVU treated its first patient in October, CAVU's adoptive T-cell therapy treatment has been administered to six dogs, O'Connor said. CAVU's T-cell therapy is currently available at more than 12 veterinary clinics across the country, including clinics in Texas, Florida, Pennsylvania, New York, North Carolina, and Missouri.

Additionally, four Houston-area clinics currently offer the T-cell therapy treatment: Garden Oaks Veterinary Clinic, Bayou City Veterinary Hospital, Memorial-610 Hospital for Animals, and Sugar Land Veterinary Specialists.

In order for a dog to be considered as a candidate — though it is ultimately up to the veterinarian on whether the T-cell therapy is right for specific dogs — the dogs must weigh more than 8 pounds, not be allergic to mouse or cow products and have no active autoimmune diseases.

The company also launched a new clinical trial with A&M University in October, looking at the effects of CAVU's T-cell therapy coupled with reduced chemotherapy periods for dogs, from roughly 19 to 26 weeks of chemotherapy to 6 to 8 weeks.

While CAVU's therapy is currently only available for dogs, O'Connor said her team plans to modify the T-cell therapy to be administered in other animals.

"We have a lot of cat owners ask us [about treatment] and we are going to do that for the next round in funding," she said. "We're going to look at how to translate this for cats and eventually horses."

O'Connor said that CAVU will launch more clinical trials with A&M University's Small Animal Hospital in the future, with CAVU aiming to make T-cell therapy treatments for cats and horses available in 2020.

Looking back, O'Connor said she has come a long way in her career path: from working with sea animals at the Newport Aquarium in Kentucky to studying human immunology and toxicology, but she's returned to studying animals.

"It's amazing how I pivoted, but at the end of the day I kind of came back to animals … and I came back full circle in a way I could have never expected," she said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

14 Houston startups starting 2026 with fresh funding

cha-ching

Houston startups closed out the last half of 2025 with major funding news.

Here are 14 Houston companies—from groundbreaking energy leaders to growing space startups—that secured funding in the last six months of the year, according to reporting by InnovationMap and our sister site, EnergyCapitalHTX.com.

Did we miss a funding round? Let us know by emailing innoeditor@innovationmap.com.

Fervo Energy

Fervo Energy has closed an oversubscribed Series E. Photo via Fervo Energy

Houston-based geothermal energy company Fervo Energy closed an oversubscribed $462 million series E funding round, led by new investor B Capital, in December.

The company also secured $205.6 million from three sources in June.

“Fervo is setting the pace for the next era of clean, affordable, and reliable power in the U.S.,” Jeff Johnson, general partner at B Capital, said in a news release.

The funding will support the continued buildout of Fervo’s Utah-based Cape Station development, which is slated to start delivering 100 MW of clean power to the grid beginning in 2026. Cape Station is expected to be the world's largest next-generation geothermal development, according to Fervo. The development of several other projects will also be included in the new round of funding. Continue reading.

Square Robot

Houston robotics co. unveils new robot that can handle extreme temperatures

Square Robot's technology eliminates the need for humans to enter dangerous and toxic environments. Photo courtesy of Square Robot

Houston- and Boston-based Square Robot Inc. announced a partnership with downstream and midstream energy giant Marathon Petroleum Corp. (NYSE: MPC) last month.

The partnership came with an undisclosed amount of funding from Marathon, which Square Robot says will help "shape the design and development" of its submersible robotics platform and scale its fleet for nationwide tank inspections. Continue reading.

Eclipse Energy

Eclipse Energy and Weatherford International are expected to launch joint projects early this year. Photo courtesy of Eclipse Energy.

Oil and gas giant Weatherford International (NASDAQ: WFRD) made a capital investment for an undisclosed amount in Eclipse Energy in December as part of a collaborative partnership aimed at scaling and commercializing Eclipse's clean fuel technology.

According to a release, joint projects from the two Houston-based companies are expected to launch as soon as this month. The partnership aims to leverage Weatherford's global operations with Eclipse Energy's pioneering subsurface biotechnology that converts end-of-life oil fields into low-cost, sustainable hydrogen sources. Continue reading.

Venus Aerospace 

Lockheed Martin Ventures says it's committed to helping Houston-based Venus Aerospace scale its technology. Photo courtesy Venus Aerospace

Venus Aerospace, a Houston-based startup specializing in next-generation rocket engine propulsion, has received funding from Lockheed Martin Ventures, the investment arm of aerospace and defense contractor Lockheed Martin, for an undisclosed amount, the company announced in November. The product lineup at Lockheed Martin includes rockets.

The investment follows Venus’ successful high-thrust test flight of its rotating detonation rocket engine (RDRE) in May. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

Venus says the Lockheed Martin Ventures investment reflects the potential of Venus’ dual-use technology for defense and commercial uses. Continue reading.

Koda Health

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health closed an oversubscribed $7 million series A funding round in October.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

The company shared that the series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space. Continue reading.

Hertha Metals

U.S. Rep. Morgan Luttrell, a Magnolia Republican, and Hertha Metals founder and CEO Laureen Meroueh toured Hertha’s Conroe plant in August. Photo courtesy Hertha Metals/Business Wire.

Conroe-based Hertha Metals, a producer of substantial steel, hauled in more than $17 million in venture capital from Khosla Ventures, Breakthrough Energy Fellows, Pear VC, Clean Energy Ventures and other investors.

The money was put toward the construction and the launch of its 1-metric-ton-per-day pilot plant in Conroe, where its breakthrough in steelmaking has been undergoing tests. The company uses a single-step process that it claims is cheaper, more energy-efficient and equally as scalable as conventional steelmaking methods. The plant is fueled by natural gas or hydrogen.

The company, founded in 2022, plans to break ground early this year on a new plant. The facility will be able to produce more than 9,000 metric tons of steel per year. Continue reading.

Helix Earth Technologies, Resilitix Intelligence and Fluxworks Inc.

Helix Earth's technology is estimated to save up to half of the net energy used in commercial air conditioning, reducing both emissions and costs for operators. Photo via Getty Images

Houston-based Helix Earth Technologies, Resilitix Intelligence and Fluxworks Inc. each secured $1.2 million in federal funding through the Small Business Innovation Research (SBIR) Phase II grant program this fall.

The three grants from the National Scienve foundation officially rolled out in early September 2025 and are expected to run through August 2027, according to the NSF. The SBIR Phase II grants support in-depth research and development of ideas that showed potential for commercialization after receiving Phase I grants from government agencies.

However, congressional authority for the program, often called "America's seed fund," expired on Sept. 30, 2025, and has stalled since the recent government shutdown. Continue reading.

Solidec Inc. (pre-seed)

7 innovative startups that are leading the energy transition in Houston

Houston-based Solidec was founded around innovations developed by Rice University associate professor Haotian Wang (far left). Photo courtesy Greentown Labs.

Solidec, a Houston startup that specializes in manufacturing “clean” chemicals, raised more than $2 million in pre-seed funding in August.

Houston-based New Climate Ventures led the oversubscribed pre-seed round, with participation from Plug and Play Ventures, Ecosphere Ventures, the Collaborative Fund, Safar Partners, Echo River Capital and Semilla Climate Capital, among other investors. Continue reading.

Molecule

Sameer Soleja is the founder and CEO of Molecule, which just closed its series B round. Photo courtesy of Molecule Software.

Houston-based energy trading risk management (ETRM) software company Molecule completed a successful series B round for an undisclosed amount, according to a July 16 release from the company.

The raise was led by Sundance Growth, a California-based software growth equity firm. Sameer Soleja, founder and CEO of Molecule, said in the release that the funding will allow the company to "double down on product innovation, grow our team, and reach even more markets." Continue reading.

Rarefied Studios, Solidec Inc. and Affekta

Houston startups were named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology this fall. Photo via NASA/Ben Smegelsky

Houston-based Rarefied Studios, Solidec Inc. and Affekta were granted awards from NASA this summer to develop new technologies for the space agency.

The companies are among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs, according to NASA.

Each selected company received $150,000 and, based on their progress, will be eligible to submit proposals for up to $850,000 in Phase II funding to develop prototypes. The SBIR program lasts for six months and contracts small businesses. Continue reading.

Intuitive Machines 

Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines secured a $9.8 million Phase II government contract for its orbital transfer vehicle in July.

The contract was expected to push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company. Intuitive Machines reported that it expected to begin manufacturing and flight integration for its orbital transfer vehicle as soon as this year, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations." Continue reading.

NRG inks new virtual power plant partnership to meet surging energy demands

Powering Up

Houston-based NRG Energy recently announced a new long-term partnership with San Francisco-based Sunrun that aims to meet Texas’ surging energy demands and accelerate the adoption of home battery storage in Texas. The partnership also aligns with NRG’s goal of developing a 1-gigawatt virtual power plant by connecting thousands of decentralized energy sources by 2035.

Through the partnership, the companies will offer Texas residents home energy solutions that pair Sunrun’s solar-plus-storage systems with optimized rate plans and smart battery programming through Reliant, NRG’s retail electricity provider. As new customers enroll, their stored energy can be aggregated and dispatched to the ERCOT grid, according to a news release.

Additionally, Sunrun and NRG will work to create customer plans that aggregate and dispatch distributed power and provide electricity to Texas’ grid during peak periods.

“Texas is growing fast, and our electricity supply must keep pace,” Brad Bentley, executive vice president and president of NRG Consumer, said in the release. “By teaming up with Sunrun, we’re unlocking a new source of dispatchable, flexible energy while giving customers the opportunity to unlock value from their homes and contribute to a more resilient grid

Participating Reliant customers will be paid for sharing their stored solar energy through the partnership. Sunrun will be compensated for aggregating the stored capacity.

“This partnership demonstrates the scale and strength of Sunrun’s storage and solar distributed power plant assets,” Sunrun CEO Mary Powell added in the release. “We are delivering critical energy infrastructure that gives Texas families affordable, resilient power and builds a reliable, flexible power plant for the grid.”

In December, Reliant also teamed up with San Francisco tech company GoodLeap to bolster residential battery participation and accelerate the growth of NRG’s virtual power plant network in Texas.

In 2024, NRG partnered with California-based Renew Home to distribute hundreds of thousands of VPP-enabled smart thermostats by 2035 to help households manage and lower their energy costs. At the time, the company reported that its 1-gigawatt VPP would be able to provide energy to 200,000 homes during peak demand.

---

This article originally appeared on EnergyCapitalHTX.com.

Rice scientist earns $600K NSF award to study distractions in digital age

fresh funding

Rice University psychologist Kirsten Adam has received a $600,000 National Science Foundation CAREER Award to research how visual distractions like phone notifications, flashing alerts, crowded screens and busy workspaces can negatively impact focus—and how the brain works to try to regain it.

The highly competitive five-year NSF grants are given to career faculty members with the potential to serve as academic models and leaders in research and education. Adam’s work will aim to clarify how the brain refocuses in the age of screens, instant gratification and other lingering distractions. The funding will also be used to train graduate students in advanced cognitive neuroscience methods, expand access to electroencephalography (EEG) and for public data sharing.

“Kirsten is a valued member of the School of Social Sciences, and we are thrilled that she has been awarded the prestigious NSF CAREER,” Rachel Kimbro, dean of social sciences, said in a news release. “Because distractions continue to increase all around us, her research is timely and imperative to understanding their widespread impacts on the human brain.”

In Adam’s lab, participants complete simplified visual search tasks while their brain activity is recorded using EEG, allowing researchers to measure attention shifts in real time. This process then captures the moment attention is drawn from a goal and how much effort it takes to refocus.

According to Rice, Adam’s work will test long-standing theories about distraction. The research is meant to have real-world implications for jobs and aspects of everyday life where attention to detail is key, including medical imaging, airport security screening and even driving.

“At any given moment, there’s far more information in the world than our brains can process,” Adam added in the release. “Attention is what determines what reaches our awareness and what doesn’t.”

Additionally, the research could inform the design of new technologies that would support focus and decision-making, according to Rice.

“We’re not trying to make attention limitless,” Adam added. “We’re trying to understand how it actually works, so we can stop designing environments and expectations that fight against it.”